
The Organisation for Economic Cooperation and Development (OECD) has warned enforcers that structural remedies may not be sufficient to remedy anticompetitive deals during the COVID-19 pandemic and urged authorities to be “extremely quick” when dealing with collaboration guidance requests.
Last week, the OECD issued guidance to help governments and antitrust authorities navigate issues around merger control, competitor collaboration and exploitative pricing in the wake of the coronavirus pandemic.
Merger control
Without a thorough merger review, there is a serious risk that the coronavirus pandemic could lead to higher market concentration and market power in several sectors, causing price increases, harm to innovation and productivity, the OECD’s competition division stated in its guidance on merger control last Monday, June 1.
The OECD warned that during unparalleled economic uncertainty, competition authorities will face key challenges in exercising merger control powers and increased pressure to speed up merger reviews. These challenges include increased uncertainty about how markets will evolve and an influx of failing firm defence claims as companies try to acquire competitors in financial difficulty, reported Global Competition Review.
Full Content: OECD, OECD, OECD
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas